Physician profile
Rajesh Kumar
NPI 1194800557
$22,649.51
in general payments reported to CMS, 2019-2025
38 companies · $5,693 in 2025
The $5,693 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,662 · 2020: $1,422 · 2021: $2,236 · 2022: $3,048 · 2023: $3,810 · 2024: $4,779 · 2025: $5,693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,808.31 |
| Education | $473.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,423.55 | 2020-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $2,397.87 | 2019-2025 | Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $2,335.07 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,695.78 | 2021-2025 | |
| Alkermes, INC. | $1,579.47 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $1,216.87 | 2022-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $1,189.07 | 2022-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $966.01 | 2020-2025 | Caplyta |
| Corium, LLC | $898.03 | 2022-2025 | Azstarys |
| Indivior INC. | $768.24 | 2019-2025 | Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $767.54 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $744.23 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $675.32 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Jazz Pharmaceuticals INC. | $521.24 | 2019-2024 | |
| Neurocrine Biosciences, INC. | $497.03 | 2019-2025 | Ingrezza |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $363.38 | 2019-2021 | |
| Adlon Therapeutics L.P. | $315.08 | 2019-2021 | |
| Braeburn INC. | $285.94 | 2024-2025 | Brixadi |
| Orexo US, INC. | $276.69 | 2020-2025 | Zubsolv |
| Almatica Pharma LLC | $272.31 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Harmony Biosciences LLC | $270.46 | 2022-2025 | |
| Tris Pharma INC | $256.32 | 2023-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Collegium Pharmaceutical, INC. | $252.96 | 2025 | Jornay Pm |
| Allergan, INC. | $236.54 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $227.26 | 2022-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $180.40 | 2024-2025 | Cobenfy |
| Gilead Sciences, INC. | $159.84 | 2019-2021 | |
| Neuronetics, INC. | $146.47 | 2019-2022 | |
| Bausch Health US, LLC | $141.59 | 2021-2022 | |
| Eisai INC. | $133.63 | 2020-2021 | |
| Sage Therapeutics, LLC | $114.13 | 2024-2025 | Zurzuvae |
| Noven Therapeutics, LLC | $99.84 | 2021-2024 | Xelstrym, Secuado |
| Neos Therapeutics, Lp | $52.90 | 2020 | |
| Vertical Pharmaceuticals, LLC | $48.16 | 2019-2025 | Relexxii |
| Uswm, LLC | $44.50 | 2021 | |
| Novo Nordisk INC | $41.29 | 2025 | Wegovy, Ozempic |
| Shire North American Group INC | $38.36 | 2019 | |
| Livanova USA, INC. | $16.14 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.